Suppr超能文献

在真实环境中应用 Lennox-Gastaut 综合征的 ILAE 诊断标准:一项多中心回顾性队列研究。

Applying the ILAE diagnostic criteria for Lennox-Gastaut syndrome in the real-world setting: A multicenter retrospective cohort study.

机构信息

Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.

Department of Neurology, Alfred Health, Melbourne, Victoria, Australia.

出版信息

Epilepsia Open. 2024 Apr;9(2):602-612. doi: 10.1002/epi4.12894. Epub 2024 Jan 24.

Abstract

OBJECTIVE

Lennox-Gastaut syndrome (LGS) is an archetypal developmental and epileptic encephalopathy, for which novel treatments are emerging. Diagnostic criteria for LGS have recently been defined by the International League Against Epilepsy (ILAE). We aimed to apply these criteria in a real-world setting.

METHODS

We applied ILAE diagnostic criteria to a cohort of patients diagnosed with LGS by epileptologists following inpatient video-EEG monitoring (VEM) at tertiary comprehensive epilepsy centers between 1995 and 2015. We also assessed mortality in this cohort.

RESULTS

Sixty patients diagnosed with LGS and had complete records available for review were identified. Among them, 29 (48%) patients met ILAE diagnostic criteria for LGS (ILAE-DC group). Thirty-one did not meet criteria (non-ILAE-DC) due to the absence of documented tonic seizures (n = 7), EEG features (n = 12), or both tonic seizures and EEG features (n = 10), intellectual disability (n = 1), or drug resistance (n = 1). The ILAE-DC group had a shorter duration of epilepsy at VEM than the non-ILAE-DC group (median = 12.0 years vs. 23.7 years, respectively; p = 0.015). The proportions of patients with multiple seizure types (100% vs. 96.7%), ≤2.5 Hz slow spike-and-wave EEG activity (100% vs. 90%), seizure-related injuries (27.6% vs. 25.8%), and mortality (standardized mortality ratio 4.60 vs. 5.12) were similar between the groups.

SIGNIFICANCE

Up to 52% of patients diagnosed with LGS following VEM may not meet recently accepted ILAE criteria for LGS diagnosis. This may reflect both the limitations of retrospective medical record review and a historical tendency of applying the LGS diagnosis to a broad spectrum of severe, early-onset drug-resistant epilepsies with drop attacks. The ILAE criteria allow the delineation of LGS based on distinct electroclinical features, potentiating accurate diagnosis, prognostication, and management formulation. Nonetheless, mortality outcomes between those who did and did not meet ILAE diagnostic criteria for LGS were similarly poor, and both groups suffered high rates of seizure-related injury.

PLAIN LANGUAGE SUMMARY

More than half of patients diagnosed with Lennox-Gastaut Syndrome (LGS) at three Australian epilepsy monitoring units between 1995 and 2015 did not meet the recently devised International League Against Epilepsy (ILAE) diagnostic criteria for LGS. Mortality was equally high in those who did and did not meet the ILAE diagnostic criteria, and seizure-related injury was common. The ILAE diagnostic criteria will guide accurate diagnosis, management, prognostication, and research in patients with LGS, however may be limited in their practical application to patients with a longer duration of epilepsy, or to those for whom detailed assessment is difficult.

摘要

目的

Lennox-Gastaut 综合征(LGS)是一种典型的发育性和癫痫性脑病,目前正在出现新的治疗方法。最近国际抗癫痫联盟(ILAE)已经为 LGS 定义了诊断标准。我们旨在将这些标准应用于真实环境中。

方法

我们应用 ILAE 诊断标准,对在 1995 年至 2015 年期间在三级综合癫痫中心接受住院视频脑电图监测(VEM)的癫痫专家诊断为 LGS 的患者队列进行评估。我们还评估了该队列的死亡率。

结果

确定了 60 名诊断为 LGS 且病历记录完整可供审查的患者。其中,29 名(48%)患者符合 ILAE 的 LGS 诊断标准(ILAE-DC 组)。31 名不符合标准(非 ILAE-DC),因为缺乏记录的强直发作(n=7)、脑电图特征(n=12)或强直发作和脑电图特征(n=10)、智力障碍(n=1)或耐药性(n=1)。与非 ILAE-DC 组相比,ILAE-DC 组在 VEM 时癫痫的持续时间更短(中位数分别为 12.0 年和 23.7 年,p=0.015)。两组患者的多种发作类型(100%与 96.7%)、≤2.5Hz 慢棘慢波脑电图活动(100%与 90%)、与发作相关的损伤(27.6%与 25.8%)和死亡率(标准化死亡率比 4.60 与 5.12)相似。

意义

在 VEM 后诊断为 LGS 的患者中,多达 52%可能不符合最近接受的 ILAE LGS 诊断标准。这可能反映了回顾性病历审查的局限性,以及将 LGS 诊断应用于广泛的严重、早发性耐药性癫痫伴猝倒的历史趋势。ILAE 标准允许根据独特的临床电特征来划定 LGS,从而促进准确的诊断、预后和管理方案的制定。尽管如此,符合和不符合 ILAE LGS 诊断标准的患者的死亡率同样较差,两组患者都有很高的与发作相关的损伤发生率。

相似文献

2
Lennox Gastaut Syndrome - A strategic shift in diagnosis over time?
Seizure. 2022 Dec;103:68-71. doi: 10.1016/j.seizure.2022.10.020. Epub 2022 Oct 28.
3
4
Real-world use of the updated refractory epilepsy screening tool for Lennox-Gastaut syndrome.
Epilepsia Open. 2024 Aug;9(4):1277-1286. doi: 10.1002/epi4.12952. Epub 2024 May 10.
5
Understanding Lennox-Gastaut syndrome: insights from focal epilepsy patients with Lennox-Gastaut features.
J Neurol. 2017 Jul;264(7):1388-1396. doi: 10.1007/s00415-017-8535-7. Epub 2017 Jun 5.
6
Lennox-Gastaut syndrome: a comprehensive review.
Neurol Sci. 2018 Mar;39(3):403-414. doi: 10.1007/s10072-017-3188-y. Epub 2017 Nov 9.
7
Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
Epilepsy Behav. 2020 Sep;110:107146. doi: 10.1016/j.yebeh.2020.107146. Epub 2020 Jun 18.
8
Long-term outcomes and adaptive behavior in adult patients with Lennox-Gastaut syndrome.
Epilepsia Open. 2024 Oct;9(5):1881-1890. doi: 10.1002/epi4.13024. Epub 2024 Aug 7.
9
Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Epilepsy Behav. 2018 Nov;88:66-73. doi: 10.1016/j.yebeh.2018.08.032. Epub 2018 Sep 18.

本文引用的文献

1
3
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study.
Seizure. 2021 Oct;91:159-166. doi: 10.1016/j.seizure.2021.05.025. Epub 2021 Jun 9.
4
Anti-seizure medications for Lennox-Gastaut syndrome.
Cochrane Database Syst Rev. 2021 Apr 7;4(4):CD003277. doi: 10.1002/14651858.CD003277.pub4.
5
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies.
CNS Drugs. 2021 Jan;35(1):61-83. doi: 10.1007/s40263-020-00784-8. Epub 2021 Jan 21.
6
The severe epilepsy syndromes of infancy: A population-based study.
Epilepsia. 2021 Feb;62(2):358-370. doi: 10.1111/epi.16810. Epub 2021 Jan 21.
7
Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
J Korean Med Sci. 2020 Dec 28;35(50):e427. doi: 10.3346/jkms.2020.35.e427.
9
Mortality in patients with psychogenic nonepileptic seizures.
Neurology. 2020 Aug 11;95(6):e643-e652. doi: 10.1212/WNL.0000000000009855. Epub 2020 Jul 20.
10
The refractory epilepsy screening tool for Lennox-Gastaut syndrome (REST-LGS).
Epilepsy Behav. 2019 Jan;90:148-153. doi: 10.1016/j.yebeh.2018.11.016. Epub 2018 Dec 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验